Valsartan/Celecoxib/Metformin

缬沙坦/塞来昔布/二甲双胍

Report date: 2022/11/25 18:07:01

Base Information

Drug NameValsartan/Celecoxib/Metformin

Drug Alias Name二甲双胍/塞来昔布/缬沙坦Celecoxib/Metformin/ValsartanCelecoxib/Valsartan/Metformin二甲双胍/缬沙坦/塞来昔布Valsartan/Metformin/Celecoxib +[11]

ClassificationSmall molecules

Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsCyclooxygenase-2 inhibitors

TargetsAngiotensin II Receptor Type 1Cyclooxygenase-2Protein kinase AMP-activated non-catalytic subunit beta 1

Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Hypertension +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsYes Metformin Hydrochloride Valsartan Celecoxib

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesArkay Therapeutics Llc

China Registration ClassN/A

Develop Information

Active CompaniesArkay Therapeutics Llc

Inactive CompaniesN/A

Active IndicationsObesityDiabetes Mellitus, Type 2Hypertension +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A